Co-administration with CYP3A4 inhibitors

Lumeva · Episodic migraine

MI-2026-0040RoutineArchivedWithin SLA

FAFatima Al-SayedMedical Information Lead

Received: 16 Mar 2026, 07:31 UTC
Channel: Phone
Requestor type: Patient
Country / region / team: Brazil · Latin America · MI APAC
Category: Drug interaction
Response type: Standard response
Owner: FAFatima Al-Sayed
Due: 21 Mar 2026, 07:31 UTC
Responded: 18 Mar 2026, 09:31 UTC
Quality review: Not required
Related insight: —
Related standard response: SR-LMV-007 · Co-administration with CYP3A4 inhibitors (v3)

Workflow

12-stage inquiry workflow (PRD §16). Advancing records an audit event.

Current stageArchivedDemo action — not persisted

Routine: 120 h target · Routine 120 h / Urgent 48 h / Critical 24 h

SLA hours

120

Elapsed

50 h

to response

Remaining

70 h

42%

16 Mar 2026, 07:31 UTC
Received via Phone
Patient · Brazil
16 Mar 2026, 07:31 UTC
Triage and assignment
Urgency Routine · assigned to MI APAC
18 Mar 2026, 09:31 UTC
Response sent
Standard response · quality review not required
21 Mar 2026, 07:31 UTC
SLA due (120 h)

Demo — drafts are not persisted

AI suggestion available for non-safety inquiries

Draft response

Timestamp	Action	User	Field	Change	Reason	Source	Event
06 Sept 2026, 06:37 UTC	Update	Luis Ortega	status	— → Completed	—	Integration	AUD-002015
01 Sept 2026, 14:03 UTC	Update	David Chen	status	Draft → Reviewed	—	API	AUD-002061

Data lineage: MI inquiry platform (IRMS, INT-05) · received 16 Mar 2026 · hourly sync.